Vitamin D deficiency and heart disease

Kidney International Supplements

Volumn 1, Issue 4, 2011, Pages 111-115

  Pilz, Stefan ^a,b   Tomaschitz, Andreas ^a   Drechsler, Christiane ^c   De Boer, Rudolf A ^d  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF WÜRZBURG   (Germany)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

cholecalciferol; epidemiology; ergocalciferol; mortality; recommendation

Indexed keywords

EID: 84862154730     PISSN: 21571724     EISSN: 21571716     Source Type: Journal    
DOI: 10.1038/kisup.2011.26     Document Type: Review

References (81)

1. Verstuyf A, Carmeliet G, Bouillon R et al. Vitamin D: a pleiotropic hormone. Kidney Int 2010; 78: 140-145.
2. Bouillon R, Carmeliet G, Verlinden L et al. Vitamin D and human health: lessons from vitamin D receptor null mice. Endocr Rev 2008; 29: 726-776.
3. Souberbielle JC, Body JJ, Lappe JM et al. Vitamin D and musculoskeletal health, cardiovascular disease, autoimmunity and cancer: recommendations for clinical practice. Autoimmun Rev 2010; 9: 709-715.
4. Pilz S, Tomaschitz A, Drechsler C et al. Vitamin D supplementation: a promising approach for the prevention and treatment of strokes. Curr Drug Targets 2011; 12: 88-96.
5. Pittas AG, Chung M, Trikalinos T et al. Systematic review: Vitamin D and cardiometabolic outcomes. Ann Intern Med 2010; 152: 307-314.
6. Pilz S, Tomaschitz A, Obermayer-Pietsch B et al. Epidemiology of vitamin D insufficiency and cancer mortality. Anticancer Res 2009; 29: 3699-3704.
7. Ravani P, Malberti F, Tripepi G et al. Vitamin D levels and patient outcome in chronic kidney disease. Kidney Int 2009; 75: 88-95.
8. Mehrotra R, Kermah DA, Salusky IB et al. Chronic kidney disease, hypovitaminosis D, and mortality in the United States. Kidney Int 2009; 76: 977-983.
9. Wolf M, Shah A, Gutierrez O et al. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int 2007; 72: 1004-1013.
10. Barreto DV, Barreto FC, Liabeuf S et al. Vitamin D affects survival independently of vascular calcification in chronic kidney disease. Clin J Am Soc Nephrol 2009; 4: 1128-1135.
11. Wang AY, Lam CW, Sanderson JE et al. Serum 25-hydroxyvitamin D status and cardiovascular outcomes in chronic peritoneal dialysis patients: a 3-y prospective cohort study. Am J Clin Nutr 2008; 87: 1631-1638.
12. Drechsler C, Pilz S, Obermayer-Pietsch B et al. Vitamin D deficiency is associated with sudden cardiac death, combined cardiovascular events, and mortality in haemodialysis patients. Eur Heart J 2010; 31: 2253-2261.
13. Drechsler C, Verduijn M, Pilz S et al. Vitamin D status and clinical outcomes in incident dialysis patients: results from the NECOSAD study. Nephrol Dial Transplant 2011; 26: 1024-1032.
14. Mehrotra R, Kermah D, Budoff M et al. Hypovitaminosis D in chronic kidney disease. Clin J Am Soc Nephrol 2008; 3: 1144-1151.
15. Doorenbos CR, von den Born J, Navis G et al. Possible renoprotection by vitamin D in renal disease: beyond mineral metabolism. Nat Rev Nephrol 2009; 5: 691-700.
16. Holick MF. Vitamin D deficiency. N Engl J Med 2007; 357: 266-281.
17. Helvig CF, Cuerrier D, Hosfield CM et al. Dysregulation of renal vitamin D metabolism in the uremic rat. Kidney Int 2010; 78: 463-472.
18. Kandula P, Dobre M, Schold JD et al. Vitamin D supplementation in chronic kidney disease: a systematic review and meta-analysis of observational studies and randomized controlled trials. Clin J Am Soc Nephrol 2011; 6: 50-62.
19. Gal-Moscovici A, Sprague SM. Use of vitamin D in chronic kidney disease patients. Kidney Int 2010; 78: 146-151.
20. Peterlik M, Cross HS. Vitamin D and calcium deficits predispose for multiple chronic diseases. Eur J Clin Invest 2005; 35: 290-304.
21. Chen S, Glenn DJ, Ni W et al. Expression of the vitamin d receptor is increased in the hypertrophic heart. Hypertension 2008; 52: 1106-1112.
22. Tishkoff DX, Nibbelink KA, Holmberg KH et al. Functional vitamin D receptor (VDR) in the t-tubules of cardiac myocytes: VDR knockout cardiomyocyte contractility. Endocrinology 2008; 149: 558-564.
23. Li YC, Kong J, Wei M et al. 1,25-dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 2002; 110: 229-238.
24. Simpson RU, Hershey SH, Nibbelink KA. Characterization of heart size and blood pressure in the vitamin D receptor knockout mouse. J Steroid Biochem Mol Biol 2007; 103: 521-524.
25. Zhou C, Lu F, Cao K et al. Calcium-independent and 1,25(OH2)D3-dependent regulation of the renin-angiotensin system in 1a-hydroxylase knockout mice. Kidney Int 2008; 74: 170-179.
26. Xiang W, Kong J, Chen S et al. Cardiac hypertrophy in vitamin D receptor knockout mice: role of the systemic and cardiac renin-angiotensin systems. Am J Physiol Endocrinol Metab 2005; 288: 125-132.
27. Yuan W, Pan W, Kong J et al. 1,25-dihydroxyvitamin D3 suppresses renin gene transcription by blocking the activity of the cyclic AMP response element by the renin gene promoter. J Biol Chem 2007; 282: 29821-29830.
28. Gardner DG, Glenn D, Ni W et al. Cardiomyocyte-specific vitamin D receptor gene knockout causes cardiac hypertrophy. Abstract at the 14th Workshop on Vitamin D, 4-8 October 2009, Brugge, Belgium, 2009.
29. Wu J, Garami M, Cheng T et al. 1,25(OH)2 Vitamin D3 and retinoic acid antagonize endothelin-stimulated hypertrophy of neonatal rat cardiac myocytes. J Clin Invest 1996; 97: 1577-1588.
30. Nibbelink KA, Tishkoff DX, Hershey SD et al. 1,25(OH)2Vitamin D3 actions on cell proliferation, size, gene expression, and receptor localisation, in the HL-1 cardiac myocyte. J Steroid Biochem Mol Biol 2007; 103: 533-537.
31. O'Connell TD, Simpson RU. 1,25-dihydroxyvitamin D3 regulation of myocardial growth and c-myc levels in the rat heart. Biochem Biophys Res Commun 1995; 213: 59-65.
32. O'Connell TD, Berry JE, Jarvis AK et al. 1,25-dihydroxyvitamin D3 regulation of cardiac myocyte proliferation and hypertrophy. Am J Physiol 1997; 272: H1751-H1758.
33. Pilz S, Tomaschitz A, Drechsler C et al. Vitamin D deficiency and myocardial diseases. Mol Nutr Food Res 2010; 54: 1103-1113.
34. Green JJ, Robinson DA, Wilson GE et al. Calcitriol modulation of cardiac contractile performance via protein kinase C. J Mol Cell Cardiol 2006; 41: 350-359.
35. Selles J, Bellido T, Boland R. Modulation of calcium uptake in cultured cardiac muscle cells by 1,25-dihydroxyvitamin D3. J Mol Cell Cardiol 1994; 26: 1539-1599.
36. Santillan GE, Vazquez G, Boland RL. Activation of a beta- adrenergicsensitive signal transduction pathway by the secosteroid hormone 1,25-(OH)2-vitamin D3 in chick heart. J Mol Cell Cardiol 1999; 31: 1095-1104.
37. Rahman A, Hershey S, Ahmed S et al. Heart extracellular matrix gene expression profile in the vitamin D receptor knockout mice. J Steroid Biochem Mol Biol 2007; 103: 416-419.
38. Timms PM, Mannan N, Hitman GA et al. Circulating MMP9, vitamin D and variation in TIMP-1 response with VDR genotype: mechanisms for inflammatory damage in chronic disorders? QJM 2002; 95: 787-796.
39. Anderson JL, May HT, Horne BD et al. Relation of vitamin D deficiency to cardiovascular risk factors, disease status, and incident events in a general healthcare population. Am J Cardiol 2010; 106: 963-968.
40. Fitzpatrick LA, Bilezikian JP, Silverberg SJ. Parathyroid hormone and the cardiovascular system. Curr Osteoporos Rep 2008; 6: 77-83.
41. Kalantar-Zadeh K, Shah A, Duong U et al. Kidney bone disease and mortality in CKD: revisiting the role of vitamin D, calcimimetics, alkaline phosphatase, and minerals. Kidney Int 2010; 78(Suppl 117): S10-S21.
42. Pilz S, Tomaschitz A, Drechsler C et al. Parathyroid hormone level is associated with mortality and cardiovascular events in patients undergoing coronary angiography. Eur Heart J 2010; 31: 1591-1598.
43. Melamed ML, Astor B, Michos ED et al. 25-hydroxyvitamin D levels, race, and the progression of kidney disease. J Am Soc Nephrol 2009; 20: 2631-2639.
44. Prietl B, Pilz S, Wolf M et al. Vitamin D supplementation and regulatory T cells in apparently healthy subjects: vitamin D treatment for autoimmune diseases? Isr Med Assoc J 2010; 12: 136-139.
45. de Zeeuw D, Agarwal R, Amdahl M et al. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet 2010; 376: 1543-1551.
46. Burgaz A, Orsini N, Larsson SC et al. Blood 25-hydroxyvitamin D concentration and hypertension: a meta-analysis. J Hypertens 2010; 29: 636-645.
47. Pilz S, Tomaschitz A. Role of vitamin D in arterial hypertension. Expert Rev Cardiovasc Ther 2010; 8: 1599-1608.
48. Takiishi T, Hysemans C, Bouillon R et al. Vitamin D and diabetes. Endocrinol Metab Clin North Am 2010; 39: 419-446.
49. Zittermann A, Frisch S, Berthold HK et al. Vitamin D supplementation enhances beneficial effects of weight loss on cardiovascular disease risk markers. Am J Clin Nutr 2009; 89: 1321-1327.
50. Karhapaa P, Pihlajamaki J, Po rsti I et al. Diverse associations of 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D with dyslipidemias. J Intern Med 2010; 268: 604-610.
51. Jorde R, Sneve M, Torjesen P et al. Parameters of the thrombogram are associated with 25-hydroxyvitamin D levels at baseline, but not affected during supplementation with vitamin D. Thromb Res 2010; 125: e210-e213.
52. Neves PL, Malho A, Cabrita A et al. Statins and vitamin D: a friendly association in pre-dialysis patients. Int Urol Nephrol 2010; 42: 173-179.
53. Sathyapalan T, Shepherd J, Arnett C et al. Atorvastatin increases 25-hydroxy vitamin D concentrations in patients with polycystic ovary syndrome. Clin Chem 2010; 56: 1696-1700.
54. Brewer LC, Michos ED, Reis JP. Vitamin D in atherosclerosis, vascular disease, and endothelial function. Curr Drug Targets 2011; 12: 54-60.
55. Garcia-Canton C, Bosch E, Ramirez A et al. Vascular calcification and 25-hydroxyvitamin D levels in non-dialysis patients with chronic kidney disease stages 4 and Nephrol Dial Transplant 2011; 26: 2250-2256.
56. Li X, Speer MY, Yang H et al. Vitamin D receptor activators induce an anticalcific paracrine program in macrophages: requirement of osteopontin. Arterioscler Thromb Vasc Biol 2010; 30: 321-326.
57. de Boer IH, Kestenbaum B, Shoben AB et al. 25-hydroxyvitamin D levels inversely associate with risk of developing coronary artery calcification. J Am Soc Nephrol 2009; 20: 1805-1812.
58. London GM, Guerin AP, Verbeke FH et al. Mineral metabolism and arterial functions in end-stage renal disease: potential role of 25-hydroxyvitamin D deficiency. J Am Soc Nephrol 2007; 18: 613-620.
59. Brown J, Nunez S, Russell M et al. Hypocalcemic rickets and dilated cardiomyopathy: case reports and review of the literature. Pediatr Cardiol 2009; 30: 818-823.
60. Testa A, Mallamaci F, Benedetto FA et al. Vitamin D receptor (VDR) gene polymorphism is associated with left ventricular (LV) mass and predicts left ventricular hypertrophy (LVH) progression in end-stage renal disease (ESRD) patients. J Bone Miner Res 2010; 25: 313-319.
61. Autier P, Gandini S. Vitamin D supplementation and total mortality: a meta-analysis of randomized controlled trials. Arch Intern Med 2007; 167: 1730-1737.
62. Wang L, Manson JE, Song Y et al. Systematic review: vitamin D and calcium supplementation in prevention of cardiovascular events. Ann Intern Med 2010; 152: 315-323.
63. Kooienga L, Fried L, Scragg R et al. The effect of combined calcium and vitamin D3 supplementation on serum intact parathyroid hormone in moderate CKD. Am J Kidney Dis 2009; 53: 408-416.
64. Blair D, Byham-Gray L, Lewis E et al. Prevalence of vitamin D [25(OH)D] deficiency and effects of supplementation with ergocalciferol (vitamin D2) in stage 5 chronic kidney disease patients. J Ren Nutr 2008; 18: 375-382.
65. Stubbs JR, Idiculla A, Slusser J et al. Cholecalciferol supplementation alters calcitriol-responsive monocyte proteins and decreases inflammatory cytokines in ESRD. J Am Soc Nephrol 2010; 21: 353-361.
66. Matias PJ, Jorge C, Ferreira C et al. Cholecalciferol supplementation in hemodialysis patients: effects on mineral metabolism, inflammation, and cardiac dimension parameters. Clin J Am Soc Nephrol 2010; 5: 905-911.
67. Jean G, Souberbielle JC, Chazot C. Monthly cholecalciferol administration in haemodialysis patients: a simple and efficient strategy for vitamin D supplementation. Nephrol Dial Transplant 2009; 24: 3799-3805.
68. Coratelli P, Petrarulo F, Buongiorno E et al. Improvement in left ventricular function during treatment of hemodialysis patients with 25-OHD3. Contr Nephrol 1984; 41: 433-437.
69. Heaney RP. Vitamin D in health and disease. Clin J Am Soc Nephrol 2008; 3: 1535-1541.
70. Hathcock JN, Shao A, Vieth R et al. Risk assessment for vitamin D. Am J Clin Nutr 2007; 85: 6-18.
71. Kidney-Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl 2009; 113: S1-S130.
72. Kalantar-Zadeh K, Kovesdy CP. Clinical outcomes with active versus nutritional vitamin D compounds in chronic kidney disease. Clin J Am Soc Nephrol 2009; 4: 1529-1539.
73. McGonigle RJ, Fowler MB, Timmis AB et al. Uremic cardiomyopathy: potential role of vitamin D and parathyroid hormone. Nephron 1984; 36: 94-100.
74. Park CW, Oh YS, Shin YS et al. Intravenous calcitriol regresses myocardial hypertrophy in hemodialysis patients with secondary hyperparathyroidism. Am J Kidney Dis 1999; 33: 73-81.
75. Lemmila S, Saha H, Virtanen V et al. Effect of intravenous calcitriol on cardiac systolic and diastolic function in patients on hemodialysis. Am J Nephrol 1998; 18: 404-410.
76. Kim HW, Park CW, Shin YS et al. Calcitriol regresses cardiac hypertrophy and QT dispersion in secondary hyperparathyroidism on hemodialysis. Nephron Clin Pract 2006; 102: 21-29.
77. Bodyak N, Ayus JC, Achinger S et al. Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals. Proc Natl Acad Sci U S A 2007; 104: 16810-16815.
78. Meems LM, van der Harst P, van Gilst WH et al. Vitamin D biology in heart failure: molecular mechanisms and systematic review. Curr Drug Targets 2011; 12: 29-41.
79. Cunningham J, Zehnder D. New vitamin D analogs and changing therapeutic paradigms. Kidney Int 2010; 79: 702-707.
80. Mizobuchi M, Nakamura H, Tokumoto M et al. Myocardial effects of VDR activators in renal failure. J Steroid Biochem Mol Biol 2010; 121: 188-192.
81. Kong J, Kim GH, Wei M et al. Therapeutic effects of vitamin D analogs on cardiac hypertrophy in spontaneously hypertensive rats. Am J Pathol 2010; 177: 622-631.